Absorption kinetics and steady-state plasma concentrations of theophylline following therapeutic doses of two sustained-release preparations
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Absorption kinetics and steady-state plasma concentrations of theophylline following therapeutic doses of two sustained-release preparations. / Andersen, O; Nielsen, M K; Eriksen, P B; Fenger, M; Knudsen, P J.
I: Journal of Pharmaceutical Sciences, Bind 72, Nr. 2, 1983, s. 158-61.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Absorption kinetics and steady-state plasma concentrations of theophylline following therapeutic doses of two sustained-release preparations
AU - Andersen, O
AU - Nielsen, M K
AU - Eriksen, P B
AU - Fenger, M
AU - Knudsen, P J
PY - 1983
Y1 - 1983
N2 - Ten healthy volunteers received two sustained-release preparations as a single and multiple dose regimen in an open crossover study. Plasma theophylline concentrations were measured by an enzyme immunoassay. The limited fluctuation of the theophylline levels at steady state, with twice daily administration, clearly demonstrated the marked sustained release properties of both preparations. Results indicate similar properties for the two preparations. Significant correlations between the single dose period and steady state were found for Cmax and AUC (r = 0.76 and 0.87, respectively) with one formulation, whereas this was not the case for the other (r = 0.27 and 0.49). The daily dose necessary to keep the plasma concentration within the therapeutic range of 55-110 mumole/liter varied from 7.9 to 22.9 mg/kg. Only mild side effects were recorded, but they were not correlated to the plasma theophylline concentration.
AB - Ten healthy volunteers received two sustained-release preparations as a single and multiple dose regimen in an open crossover study. Plasma theophylline concentrations were measured by an enzyme immunoassay. The limited fluctuation of the theophylline levels at steady state, with twice daily administration, clearly demonstrated the marked sustained release properties of both preparations. Results indicate similar properties for the two preparations. Significant correlations between the single dose period and steady state were found for Cmax and AUC (r = 0.76 and 0.87, respectively) with one formulation, whereas this was not the case for the other (r = 0.27 and 0.49). The daily dose necessary to keep the plasma concentration within the therapeutic range of 55-110 mumole/liter varied from 7.9 to 22.9 mg/kg. Only mild side effects were recorded, but they were not correlated to the plasma theophylline concentration.
M3 - Journal article
VL - 72
SP - 158
EP - 161
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
SN - 0022-3549
IS - 2
ER -
ID: 34097984